Teva Pharmaceutical Industries Limited
—- Market cap
- —
- Debt
- +$1.82B
- Cash
- −$3.56B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $62.93M · View financials
Decision snapshot: TEVA stock price vs PLCE: inconclusive — current versus $0.78 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PLCE's multiple
Implied fair value · at TEVA's multiple
Needs TEVA P/S.
Snapshot Sep 8, 2026, 1:54 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: TEVA FY 2025 (ended Dec 31, 2025) · PLCE FY 2026 (ended Jan 31, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 32% equity / 68% debt · EV / Revenue 0.16x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
THE CHILDREN’S PLACE, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.23x
-2.42x
Net debt / EBITDA
Leverage against operating earnings
-0.42x
-2.04x
Cash and equivalents
Liquid reserves on the balance sheet
$3.56B
$5.49M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Viatris Inc
TEVA vs VTRS
Organon & Co.
TEVA vs OGN
ANI PHARMACEUTICALS INC
TEVA vs ANIP
ABERCROMBIE & FITCH CO /DE/
TEVA vs ANF
FOOT LOCKER, INC.
TEVA vs FL
WOLVERINE WORLD WIDE INC /DE/
TEVA vs WWW
GAP INC
TEVA vs GAP
Sally Beauty Holdings, Inc.
TEVA vs SBH
TILLY'S, INC.
TEVA vs TLYS
$1.82B
$131.08M
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.